Showing results (81-90 of 101) with videos related to
Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|June 2, 2016
In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA GyraseChristopher M Tan, Charles J Gill, Jin Wu, et al.Bioorganic & Medicinal Chemistry Letters|May 17, 2015
Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3)Sheo B Singh, David E Kaelin, Jin Wu, et al.Antimicrobial Agents and Chemotherapy|September 25, 2004
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic propertiesDavid B Olsen, Anne B Eldrup, Linda Bartholomew, et al.The Journal of Biological Chemistry|September 11, 2003
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroGiovanni Migliaccio, Joanne E Tomassini, Steven S Carroll, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2)Sheo B Singh, David E Kaelin, Jin Wu, et al.Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.Pageof 11